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Introduction: Using cell line-based assays, the secretion of eryth-
roblastic leukemia viral oncogene homologue (ERBB) ligands has 
been reported to contribute to resistance against crizotinib in lung 
cancer with the echinoderm microtubule-associated protein-like 4 
and anaplastic lymphoma kinase fusion gene. However, it is difficult 
to predict the role of the ligands in each patient. Here, we report an 
analysis of the mechanism of resistance behind crizotinib resistance 
using a primary culture of cancer cells from pleural effusion of an 
anaplastic lymphoma kinase-positive lung cancer patient who was 
clinically resistant to crizotinib.
Methods: Primary cancer cells were prepared as cancer tissue-orig-
inated spheroids (CTOSs) according to previously described meth-
ods. CTOSs were maintained in StemPro medium, and a sensitivity 
assay was performed under growth factor-free conditions, or under 
stimulation with epidermal growth factor (EGF) or neuregulin-1/
heregulin. The effect of treatment with crizotinib alone or a combi-
nation of crizotinib and erlotinib was examined.
Results: Cancer cells (LB53) were established to be CTOSs from a 
patient who was clinically resistant to crizotinib. The CTOSs were sen-
sitive to crizotinib under growth factor-free conditions in vitro, whereas 
resistant under stimulation with EGF or neuregulin-1. These ligands 
rescued the inhibition of intracellular signaling by crizotinib. Pleural 
effusion from the patient also activated EGF receptor signaling to the 
similar extent of EGF stimulation. The resistance to crizotinib by EGF 
was reversed by blocking EGF receptor signaling by erlotinib in vitro.
Conclusion: Stimulation by ERBB ligands is suggested to be respon-
sible for resistance to crizotinib in this patient. The CTOS method 
may enable analysis of resistance mechanism for targeted therapy in 
individual patients.
Key Words: Lung cancer, Anaplastic lymphoma kinase, Crizotinib 
resistance, Primary culture, ERBB.
(J Thorac Oncol. 2015;10: 527–530)
Crizotinib is an anaplastic lymphoma kinase (ALK) inhibi-tor that shows remarkable antitumor effects in non–small-
cell lung cancer (NSCLC) patients who are positive for the 
echinoderm microtubule-associated protein-like 4 and ALK 
(EML4-ALK) translocation. Despite their initial response, 
patients with ALK-positive NSCLC treated with ALK 
inhibitors eventually acquire resistance to these drugs.1 The 
molecular mechanisms regulating such resistance are being 
extensively researched. Recently, several researchers reported 
that the activation of erythroblastic leukemia viral oncogene 
homologue (ERBB) family signaling can be a mechanism by 
which resistance is acquired.2–4 Using primary cultured cells 
from an EML4-ALK-positive tumor of a patient that was clin-
ically resistant to crizotinib, we performed an in vitro sensi-
tivity assay along with pathway activation/inhibition analysis.
RESULTS
Case Description
A 62-year-old woman was urgently admitted to our 
hospital with symptoms of productive cough and breathless-
ness. Computed tomography (CT) revealed multiple nod-
ules in both lungs, left supraclavicular lymphadenopathy, 
bilateral pleural effusion, pericardial effusion, and multiple 
bone metastases, indicating T4N3M1b lung cancer. Nodule 
biopsy revealed lung adenocarcinoma with wild-type epi-
dermal growth factor receptor (EGFR) and the EML4-ALK 
fusion gene (variant 1).
Figure 1 shows clinical course of the patient. Crizotinib 
(250 mg) was administered twice daily as the first-line treat-
ment, but serum levels of liver enzymes became elevated. The 
dose of crizotinib was reduced to 200 mg twice daily, but it 
could not be continued because of hepatic toxicity. Finally, the 
patient was able to tolerate 200 mg of crizotinib once daily.
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Computed tomography scans and chest radiography 
(Fig. 2) revealed appreciable resolution of bilateral lung 
shadows, and the serum value of carcinoembryonic antigen 
decreased (Fig. 1). The patient was discharged without oxygen 
support. After 3 months, however, the lung tumors started to 
regrow, with accumulation of pleural and pericardial effusion, 
despite the continued administration of crizotinib. Second-line 
chemotherapy of cisplatin and pemetrexed resulted in only a 
minor short-term response. The patient died of lung cancer 2 
months after initiating the second-line chemotherapy.
Sensitivity Assay of Crizotinib Using Patient-
Derived Cancer Tissue-Originated Spheroids
We successfully prepared and cultured primary cancer 
cells, LB53, from pleural effusion obtained after the start of 
the second-line chemotherapy by a recently developed primary 
culture method, the cancer tissue-originated spheroid (CTOS) 
system, which was first developed for colorectal cancer5 and 
then extended to lung cancer.6 Neither secondary mutation of 
the EML4-ALK gene nor an activating mutation of the EGFR 
gene was detected by sequencing (data not shown). A sensitiv-
ity assay was performed as previously described.6
LB53 cells were resistant to crizotinib in standard CTOS 
culture medium (StemPro hES; Invitrogen, Carlsbad, CA), 
whereas they were sensitive under growth factor-free conditions. 
Among the growth factors in the culture medium, neuregulin-1 
(NRG-1) and EGF made LB53 cells more resistant to crizotinib 
(Fig. 3A, B). The effect was specific response to crizotinib, but not 
a general effect due to different culture conditions, as CTOSs from 
a non-EML4-ALK-translocated case showed high resistance to 
crizotinib in any culture condition (Supplementary Figure 1, SDC 
1, http://links.lww.com/JTO/A727). In addition, rescue by ERBB 
ligands was not observed in cis-Diamineplatinum(II) dichloride 
(CDDP) treatment (Supplementary Figure 2, SDC 1, http://links.
lww.com/JTO/A727). Pathway activation analysis revealed that 
phosphorylation of ALK was completely blocked by 1 μM of 
crizotinib in the absence or presence of EGF and NRG-1 (Fig. 
3C). Meanwhile, EGF and NRG-1 rescued the suppression of 
ERK phosphorylation by crizotinib. Next, we assessed whether 
ERBB ligands existed in the patient’s own pleural effusion. After 
stimulation with pleural effusion drawn at two different timings 
of acquired resistance, EGFR and the downstream molecule, 
ERK, were phosphorylated to the similar extent of EGF stimu-
lation (Fig 4A). With the combined treatment of crizotinib and 
FIGURE 1.  Clinical course of the patient. Crizotinib was 
started on her 2nd day in the hospital. The solid line indicates 
serum CEA value. The arrow with LB53 indicates the time 
when pleural effusion was obtained to establish CTOSs (LB53 
cells). Time points of plural effusion sampling are indicated as 
PE 1 and PE 2. A month is defined as 28 days. CEA, carcino-
embryonic antigen; CTOSs, cancer tissue-originated spher-
oids; PE, pleural effusion.
FIGURE 2.  Chest radiography (upper panels) and 
CT (lower panels) before and after treatment with 
crizotinib. Chest radiography and chest CT examina-
tion after treatment were performed on the 28th 
day and on the 22nd day in the hospital, respec-
tively. CT, computed tomography.
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erlotinib (an EGFR inhibitor), LB53 cells were sensitive even in 
the presence of EGF (4B, C), whereas no effect was observed 
with erlotinib alone (Supplementary Figure 3A and B, SDC 1, 
http://links.lww.com/JTO/A727).
These results suggest that activation of ERBB family 
receptor tyrosine kinases might have been responsible for the 
acquired resistance to crizotinib in this patient.
DISCUSSION
Acquired resistance is the primary hurdle preventing ALK 
inhibitors from curing ALK-positive NSCLC. Several mecha-
nisms of resistance have been proposed, including secondary 
resistant mutations, amplification of the ALK fusion gene, and 
activation of other receptor tyrosine kinases.7 Among them, 
EGFR activation by secretion of EGFR ligands amphiregulin and 
EGF, and ERBB3 ligand NRG-1 by cancer cells has been shown 
to mediate crizotinib resistance by cell line-based analyses.2,4,7
These mechanisms of resistance can overlap. Therefore, 
a snapshot analysis using biopsy samples, such as assessing 
phosphorylation of EGFR, is not sufficient to predict the response 
of a patient to a combination therapy such as ALK inhibitors 
plus EGFR tyrosine kinase inhibitors. Direct assessment of sen-
sitivity to the drugs or their combination is necessary, especially 
in cases of ligand-dependent resistance, as in this report.
We tested the above-mentioned mechanisms of resistance 
using primary culture samples. The CTOS method has high effi-
ciency and purity for a primary culture of cancer cells and can be 
applied to sensitivity assay and pathway activation analysis.5,6,8 
In lung cancer, the success rate of CTOS preparation is 80.0% 
from surgical specimens and 44.4% from pleural effusion; the 
latter totally depends on the contents of cancer cells in the with-
drawn effusion.6 Although CTOS preparation from tiny biopsy 
specimens still remains challenging, CTOS can be established in 
a few days when sufficient amount of tumor cells are obtained. 
Once established, the CTOS sensitivity assay and its pathway 
activation analysis might enable the selection of suitable patients 
for combination therapy of targeted drugs. Especially, assessing 
the concentration of each ligand in culture medium might help 
FIGURE 3.  Activation of ERBB signaling by EGF or NRG-1 decreased crizotinib sensitivity. A, In vitro dose–response curve of 
crizotinib in LB53. CTOSs were cultured under growth factor-free conditions (closed circle), with 10 ng/ml of EGF (open circle), 
or with NRG-1 (open triangle); CTOSs were then treated with crizotinib for 7 days. Averages and standard deviation are shown. 
IC50 is listed above the graph. B, Representative image of CTOSs treated with 1 μM crizotinib in the presence of 10 ng/ml of 
NRG1, EGF, bFGF, activin A or 100 ng/ml of long-IGF1, IL-6, and IL-6Rα or 50 ng/ml of HGF for 7 days. C, Western blot of the 
ALK or ERBB signaling pathways in LB53. CTOSs were cultured under growth factor-free conditions and pulsed with 10 ng/ml 
of EGF or NRG-1 for 15 minutes in the presence or absence of 1 μM crizotinib. ALK, anaplastic lymphoma kinase; bFGF, basic 
fibroblast growth factor; CTOSs, cancer tissue-originated spheroids; EGF, epidermal growth factor; HGF, hepacyte growth factor; 
IC50, half maximal inhibitory concentration; NRG-1, neuregulin-1.
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determine which specific ERBB family receptor signals should 
be blocked to overcome crizotinib resistance.
This is the first report regarding preparation and culturing 
CTOSs of ALK-positive lung cancer from the pleural effusion 
of a patient whose disease was clinically resistant to crizotinib. 
Using the CTOS system, we suggested that activation of ERBB 
family receptor tyrosine kinase has facilitated a mechanism of 
resistance to crizotinib in this patient. Although these analyses 
did not contribute to her treatment itself, our results suggest that 
the sensitivity assay with primary cancer cells using the CTOS 
method may contribute to the determination of treatment strat-
egy in the era of molecular target drugs.
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FIGURE 4.  Erlotinib restored crizotinib sensitivity in the presence of EGF. A, Western blot of ALK and ERBB signaling pathways 
in LB53. CTOSs were cultured under growth factor-free conditions over night, and then stimulation for 15 minutes was per-
formed with patient’s own pleural effusion, or with the medium containing 10 ng/ml of EGF or NRG-1. Pleural effusion drawn 
at two different time points was examined (Pleural effusion 1 and 2). B, In vitro dose–response curve of crizotinib in LB53 cells. 
CTOSs were cultured in medium containing 10 ng/ml of EGF with (closed circle) or without (open circle) 1 μM of erlotinib. 
Average and standard deviation are shown. IC50 is listed above the graph. C, Western blot of ALK or the ERBB signaling pathway 
in LB53. CTOSs were cultured under growth factor-free conditions and pulsed with 10 ng/ml EGF for 15 minutes in the pres-
ence or absence of 1 μM crizotinib and/or 1 μM erlotinib. EGF, epidermal growth factor; NRG-1, neuregulin-1; CTOSs, cancer 
tissue-originated spheroids; ALK, anaplastic lymphoma kinase.
